Adult malignant brain tumors present challenging management and decision-making problems as the disease advances and are no longer treatable. In the United States, there are more than 14 000 new cases yearly with 5 cases occurring per 1 00 000 population. The incidence is increasing with age, which is attributed to the aging process along with the use of the magnetic resonance imaging (MRI) technology allowing for a better diagnostic tool. The peak incidence varies with the type of brain tumor, with a median age of 64 in gliobastoma multforme (GBM) and 45 in anaplastic astrocytoma (AA). The disease is more common in men and whites and in less than 5% is a family history positive. Only a few rare inherited diseases, such as neurofibromatosis types 1 and 2, Li-Fraumeni, and Turcot syndromes, are at risk for brain tumors. In the vast majority of cases, there are no genetic causes. The only established risk factor is exposure to ionizing radiation. The association with cell phone use is not a proven risk factor nor is living close to the electromagnetic fields. 1 Symptoms of brain tumors include headache, altered mental status, seizures, and focal neurological lateralizing signs. Although the classic severe headache occurring upon wakening in the morning and lasting all day may occur, this headache often mimics a tension headache and is ignored by the patient. What appears to be more common are the subtle mental aberrations including memory loss, intermittent confusion, difficulty in finding the right words, and similar complaints. Since the peak age of GBM incidence is in the 60s, these cognitive changes are often attributed to aging by the patient and the family. Presenting seizures, both focal and grand mal, can occur as well as other lateralizing neurological findings. But, overall, the presenting symptomology of brain tumors is subtle and often overlooked by the patient and the family.
Types of brain tumors in adults and frequency include:
GBM: 60% to 70%; AA: 10% to 15%; Anaplastic oligodendroglioma (AOD): 10%; Low-grade gliomas (astrocytoma and oligodendroglioma;
LGG): 10%.
The vast majority (95%) of GBMs occur spontaneously through a malignant transformation of normal neural stem cells resulting from the accumulation of genetic aberrations and defects in growth factor signaling pathways. 1 Few (5%) arise from a preexisting LGG over the course of 10 years. Certain prognostic markers have been identified in brain tumors, some of which are therapeutically important. For example, the deletion of chromosomes 1p and 19q in AOD predicts chemotherapy sensitivity as well as a longer survival. Recent attention has been focused on the promoter gene methylguanine methyltransferase (MGMT) in GBM. When unmethylated, this gene promotes DNA repair, thus reversing the damaging effects of both radiation and chemotherapy on the malignant cells. Methylating this gene turns off the DNA repair allowing for the intended effects of the cell kill. In a landmark study, Stupp et al 2,3 demonstrated a significantly improved survival in patients with GBM treated with radiation therapy combined with chemotherapy (temozolomide) versus radiation therapy alone:
Median survival of 14.6 months versus 12.1 months; 2-year survival rate of 26.5% versus 10%; 5-year survival rate of 9.8% versus 1.9%.
In addition, methylated MGMT (45% of the patients) was a strong predictor of outcome and benefit from temozolomide chemotherapy. Maximal surgical reduction prior to the above combined chemoradiation is an important treatment strategy.
It is beyond the scope of this short review of brain tumors to discuss the multiple twists and turns in new treatment paradigms, but it must be noted that the prognosis of GBM, however grim it seems, has changed over the past 10 years, enabling patients to live longer but with a whole new set of chronic disease problems. The first of these is the propensity to develop blood clots, usually a deep vein thrombosis (DVT) often leading to pulmonary embolism (PE) requiring anticoagulation. Another problem relates to steroid use, generally dexamethasone (Decadron). Steroids are the frontline treatment when the patient presents with a brain tumor and cerebral edema. The optimal dose of 16 mg/d of dexamethasone can control this brain swelling until the initial therapy is started. After surgery, the dose is decreased as the edema subsides. However, during the course of the radiation therapy, the edema may recur and worsen requiring the reinstitution or increasing the dexamethasone dose. During the subsequent course of the disease, the steroid dose may be adjusted depending on the clinical symptoms such as headache. This continued use of dexamethasone, if it cannot be stopped, leads to a proximal myopathy, predominantly in the thighs. This in turn significantly impairs ambulation since the patient has great difficulty rising from a sitting position and leads to a wheelchairbound patient. Therefore, risk for DVT is significantly increased beyond the baseline. This particular vicious clinical cycle is difficult to break and careful attention to discontinuing the steroids whenever possible should be made.
What has not been particularly well studied are the symptoms as patients with brain tumors progress to the end-of-life. To investigate this, Sizoo et al 4 retrospectively studied 58 patients over the age of 18 years who had died during a 3.5-year period following treatment at the VU University Medical Centre in Amsterdam. The authors defined the end-of-life phase as the period when the disease progressed and there was no further treatment or the patient refused any further treatment. The group was robust, with the majority being male (67%), median age of 52 at diagnosis, slightly less than three-quarters (71%) had a GBM, median survival of 12 months, 46-day median duration of the end-of-life phase, and more than half (66%) died at home. Of the 58 patients, 3 were lost to follow-up in the end-of-life phase, leaving 55 patients for analysis.
In the 55 patients, the following symptoms were documented in the end-of-life phase: drowsiness/progressive loss of consciousness: 87%; dysphagia: 71%; progressive focal neurological deficits (motor deficit, coordination loss, and/or aphasia): 51%; seizures: 45%; urinary incontinence (before the patient was bed bound): 40%; headache: 33%; progressive cognitive deficits (memory loss, personality changes, apathy, and problems in executive functioning and understanding): 33%; confusion/agitation: 29%; bodily pain (often related to immobilization): 25%.
Additional symptoms reported by the patients and caregivers were: fatigue:25%; nausea/vomiting: 20%; dyspnea (pneumonia, PE): 16%; steroid side effects (steroid myopathy, hyperglycemia, bowel perforation):14%; constipation (due to morphine): 9%; anxiety/depression: 9%.
Of all the symptoms, drowsiness and dysphagia occurred most frequently during the last week of life. In 40 (73%) of the 55 patients, the presumed cause of death was brain herniation due to tumor progression. As noted by the authors, the prevalence of symptoms related to increased intracranial pressure (headache and drowsiness), neurological deficits, seizures, and cognitive dysfunction were similar to other studies. The finding of urinary incontinence in 40% was surprising and the etiology was unclear; however, the authors speculated that this may be related to tumor location or due to loss of consciousness. Although not specifically commented on by the authors, they observed that 80% of the patients during the end-of-life phase were on steroids and 14% experienced a steroid-related side effect. Finally, the authors concluded that patients with malignant brain tumors had specific symptoms during the end-of-life phase, which differed from the terminally ill patients dying from other cancers. Appreciating these symptoms in this patient population is important not only for their management but also to maintain as much quality of life for the patient as possible.
Part II of the adult malignant brain tumors: palliative medicine issues will address decision-making problems and other caveats.
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